-
Br J Cancer: Clinical study of Berzosertib combined with cisplatin in the treatment of patients with advanced solid tumors
Time of Update: 2021-06-10
The combination therapy of berzosertib and cisplatin is well tolerated, and it has shown preliminary clinical activity in patients with advanced solid tumors.
The combination therapy of berzosertib and cisplatin is well tolerated, and it has shown preliminary clinical activity in patients with advanced solid tumors.
-
ASCO 2021: Summary Overview and Outlook 5 Dana-Farber Cancer Institute ASCO Key Research Focus
Time of Update: 2021-06-10
Choueiri, MD, Director of the Ranke Urogenital Oncology Center, Dana-Farber Cancer Institute, will present results from the randomized, double-blind, phase III KEYNOTE-564 trial, which evaluated pembrolizumab versus placebo The postoperative efficacy of renal cell carcinoma patients (abstract LBA5) will be held at the ASCO plenary meeting on June 6, 2021 (Sunday) 1:00 pm-4:00 pm Eastern Time.
-
Cancer Sci: Aletinib can effectively and safely treat relapsed or refractory ALK-positive lymphoma
Time of Update: 2021-06-10
An open-label phase II trial aims to study the efficacy and safety of the second-generation ALK inhibitor aletinib in patients with relapsed or refractory ALK-positive asexual large cell lymphoma (ALCL).
-
ASCO 2021: Summary Overview and Outlook 3 Roche atezolizumab is expected to be the first immunotherapy approved for perioperative treatment of non-small cell lung cancer
Time of Update: 2021-06-10
Roche Art Zhu monoclonal antibody (Tecentriq) is expected to become the first to be approved for perioperative treatment of non-small cell lung cancer immunity data Impower-010 in the study therapy, the study was just released Virtual Asco meeting on aid research Derived from.
-
ASCO 2021: New progress in skin cancer immunotherapy (continuous update)
Time of Update: 2021-06-10
Nivolumab alone in the treatment of advanced melanoma (Abstract 9503)The RELATIVITY-047 study showed that the treatment of anti-PD-1 therapy nivolumab plus LAG-3 blocking antibody relatlimab prolonged the time of disease progression in patients with previously untreated, unresectable or metastatic melanoma.
-
Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC
Time of Update: 2021-06-10
( TSE:4502/NYSE:TAK ) ("Takeda") today released mobocertinib (TAK-788) for oral treatment of epidermal growth factor receptor (EGFR) Exon 20 insertion mutation positive (insert+) metastatic non-small cell lung cancer (m NSCLC ) Phase 1/2 clinical trial data.
-
JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs)
Time of Update: 2021-06-10
The 5-year risk of tumor-specific death in the overall population of NETs is higher than that of non-tumor-related deaths, with mortality rates of 7.
The 5-year risk of tumor-specific death in the overall population of NETs is higher than that of non-tumor-related deaths, with mortality rates of 7.
-
ASCO 2021: Overview of Oral Abstracts for Metastatic Breast Cancer Special Session
Time of Update: 2021-06-10
1000The Phase III MONALEESA-3 trial (NCT02422615) has demonstrated that in postmenopausal patients with HR+/HER2-ABC, RIB (a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)) plus FUL and placebo Compared with (PBO) plus FUL as first-line (1L) or second-line (2L) treatment, OS has a significant improvement (median, less than VS.
-
ASCO 2021: Summary Overview and Outlook 2
Time of Update: 2021-06-10
ASCO 2021: Summary Overview and Outlook 1ASCO 2021: Summary Overview and Outlook 1 For followers of the academic progress of oncology, the release of the Asco summary is one of the biggest events of t
-
Shukun's coronary AI and pneumonia AI have obtained the EU MDR CE certificate. Smart medical health services benefit doctors and patients around the world
Time of Update: 2021-06-10
diagnosisCE certification is the entry threshold required for medical device products to enter most countries centered on Europe, while MDR is a new version of the regulations issued by the European Commission in compliance with the development of the medical device industry, which proposes changes to the clinical evaluation and testing of products before marketing.
-
JCO: Using PET imaging to evaluate the significance of early treatment response to the prognosis of esophageal/esophageal-gastric junction cancer
Time of Update: 2021-06-10
4 monthsIn conclusion, the use of PET imaging as a biomarker for individualized early response assessment of patients with adenocarcinoma at the esophagus and esophagogastric junction is effective and improves the pCR rate of PET non-responders .
-
ASCO 2021: Non-Small Cell Lung Cancer Special Session-Oral Report (01)
Time of Update: 2021-06-10
G12C mutant non-small cell lung cancerOverall survival and exploratory subgroup analysis from the Phase 2 trial of CodeBreaK 100 to evaluate the efficacy of sotorasib in preconditioned KRAS p.
-
Lancet Oncol: Short-term results of laparoscopic right colon cancer resection, CME VS. D2 resection
Time of Update: 2021-06-10
The primary endpoint is the 3-year disease-free survival rate, but the data for this endpoint is not yet mature; therefore, this article only reports the secondary results-intraoperative complications and complications within 30 days after surgery (according to the Clavien-Dindo classification), death Rate (all-cause death within 30 days after surgery), and the rate of central lymph node metastasis in the CME group.
-
Front Cell Infect Microbiol: Still not brushing your teeth well?
Time of Update: 2021-06-10
Proto-Oncogenes and Cell Cycle Gene Expression in Normal and Neoplastic Oral Epithelial Cells Stimulated With Soluble Factors From Single and Dual Biofilms of Candida albicans and Staphylococcus aureusStudies have found that fungi and bacteria in the oral cavity not only cause diseases such as periodontitis and dental caries, but also activate the expression of head and neck cancer-related genes.
-
2021 ASCO Conference Schedule Preview 1 (June 4)
Time of Update: 2021-06-10
The first phase I clinical study of a new PARP7 inhibitor-RBN-2397 in patients with advanced solid tumors1.
The first phase I clinical study of a new PARP7 inhibitor-RBN-2397 in patients with advanced solid tumorsPARP inhibitor is a medical agent that can affect the self-replication mode of cancer cells.
-
JNCI: Obesity and lack of exercise increase the risk of breast cancer. What impact will it have on the results of chemotherapy?
Time of Update: 2021-06-10
World Cancer Research Fund will have 82 Assessment I-III breast cancer and women's body mass index (BMI) and report the relationship between mortality conducted a meta-analysis, found that compared with normal-weight women, the diagnosis when breast cancer, Breast cancer-related mortality among obese women increased by 35%, and overall mortality increased by 41%.
-
Int J Clin Oncol: Tisagenlecleucel can effectively and safely treat certain Japanese R/R DLBCL patients
Time of Update: 2021-06-10
In the pivotal global Phase 2 JULIET study, Tisagenlecleucel showed a high sustained response rate in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
, Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma .
-
ASCO 2021: The Voice of China!
Time of Update: 2021-06-10
2021 On 6 Yue 7 May 2021 annual ASCO (American Society of Clinical Oncology) Annual Meeting at the plenary session " heavy Abstract " ( LBA , Late-Breaking the Abstract ) form, the king issued a real biological self-developed anti- PD- 1 The latest results of the first-line treatment of relapsed / metastatic nasopharyngeal carcinoma ( Jupiter-02 study) with the monoclonal antibody drug teriprolizumab combined with chemotherapy .
-
ASCO 2021: The next wave of radiation oncology revolution: radiopharmaceuticals track and kill cancer cells
Time of Update: 2021-06-10
As a result, doctors reported that men with advanced prostate cancer who received an experimental drug that provided radiation directly to tumor cells had an improved survival rate.
-
The case fatality rate and mortality rate are so high, early screening for gastric cancer should not be taken lightly!
Time of Update: 2021-06-10
South Korea also launched a nationwide community-based gastric cancer screening in the 1990s, which increased the early gastric cancer detection rates in these two countries to 70% and 55%, respectively, and the 5-year survival rate of gastric cancer patients was as high as 64.
